Romosozumab following denosumab improves lumbar spine bone mineral density and trabecular bone score greater than denosumab continuation in postmenopausal women

• Published in: Journal of bone and mineral research 2024-11
• Main Authors: Hong, Namki, Shin, Sungjae, Kim, Hyunjae, Cho, Sung Joon, Park, Jin Ah, Rhee, Yumie
• Format: Article
• Language: English
• ISSN: 0884-0431; 1523-4681; 1523-4681
• DOI: 10.1093/jbmr/zjae179

Romosozumab following anti-resorptive can be an effective sequential treatment strategy to improve bone strength. However, whether the transition to romosozumab after denosumab is associated with greater improvement in bone mineral density (BMD) and trabecular bone score (TBS) compared to denosumab continuation remains unclear. In this propensity score-matched cohort study, we analyzed data from postmenopausal women who initiated denosumab between 2017 and 2020. Individuals who were transited to 12 months of romosozumab after denosumab were 1:1 matched to those who continued an additional 12 months of denosumab (n = 86 for each group; denosumab-romosozumab [DR] and denosumab-denosumab [DD]). Mean BMD gain by denosumab treatment in matched DR and DD groups from denosumab initiation to transition (median 4 times [range 2 to 8]) was +4.8% and + 2.0% in the lumbar spine and total hip. DR group showed greater LS BMD gain compared to the DD group (+6.8 vs. +3.3% point, P